Know Cancer

forgot password

A Phase I/II Trial of PTC299 in Patients With HIV-Related Kaposi's Sarcoma

Phase 1/Phase 2
18 Years
Not Enrolling
Kaposi's Sarcoma

Thank you

Trial Information

A Phase I/II Trial of PTC299 in Patients With HIV-Related Kaposi's Sarcoma



- To define the safety and toxicity of anti-VEGF small molecule PTC299 in patients with
HIV-related Kaposi sarcoma.

- To establish the maximum tolerated dose of this drug in these patients.

- To estimate the response rate in patients treated with this drug.


- To describe the pharmacokinetics of this drug in these patients.

- To describe the effects of this drug on serum and plasma VEGF, VEGFR, and cytokine
profiles in these patients.

- To describe the effects of this drug on HIV and KSHV viral loads in these patients.

- To describe the effects of this drug on T-lymphocyte subsets (i.e., CD4 and CD8) in
these patients.

- To describe the effects of this drug on VEGF, VEGFR-2 and -3, phospho-Akt, p53, and
HIF-1α expression and tumor cell proliferation, as measured by Ki-67 staining, in tumor
biopsy samples obtained from these patients.

- To describe the effects of this drug on viral gene expression and cellular gene
transcription, as measured by real-time quantitative PCR-based profiling, in tumor
biopsy samples obtained from these patients.

OUTLINE: This is a multicenter, phase I dose-escalation study of anti-VEGF small molecule
PTC299 followed by a phase II study.

Patients receive oral anti-VEGF small molecule PTC299 twice daily on days 1-28. Treatment
repeats every 28 days for up to 12 courses in the absence of disease progression or
unacceptable toxicity. Patients who do not demonstrate an objective response of their Kaposi
sarcoma (KS) lesions after 6 courses of treatment are removed from the study.

Patients undergo blood sample collection and punch biopsies periodically during study for
correlative laboratory studies. Biopsy samples are assessed for VEGF, VEGFR-2, VEGFR-3,
phospho-Akt, KSHV LANA, orf59, p53, and HIF-1α expression by IHC; tumor cell proliferation
by Ki-67 staining; and viral gene expression at the messenger RNA level and KSHV
transcription by real-time quantitative PCR-based profiling. Blood samples are assessed for
pharmacokinetics and levels of secreted cytokines or other potential serum markers
characteristic for KS.

After completion of study treatment, patients are followed at 30 days.

Inclusion Criteria


- Biopsy-proven Kaposi sarcoma (KS) involving the skin (with or without lymph node),
oral cavity, gastrointestinal (GI) tract, and/or lung

- Patients with GI and/or pulmonary involvement must be asymptomatic or minimally
symptomatic and not require systemic cytotoxic chemotherapy

- Has at least five bidimensionally measurable cutaneous lesions that have not been
previously irradiated AND can be used as indicator lesions

- Must have a sufficient number of non-indicator cutaneous lesions measuring ≥ 4 x
4 mm available to obtain a total of four 3-mm punch biopsies (two at baseline
and two during the course of study treatment)

- Serologic documentation of HIV infection, as evidenced by positive ELISA, western
blot, or other federally approved licensed HIV test OR a detectable blood level of

- Patients receiving antiretroviral therapy for HIV infection are eligible provided
they have been on a stable regimen for ≥ 12 weeks prior to study entry AND there is
no evidence of improvement in KS during those 12 weeks or there is evidence of
progression of KS within the immediate 4 weeks prior to study entry

- No symptomatic visceral KS requiring cytotoxic therapy


- Karnofsky performance status 60-100%

- Life expectancy ≥ 3 months

- Absolute neutrophil count ≥ 1,000/mm³

- Platelet count ≥ 75,000/mm³

- Hemoglobin ≥ 8 g/dL

- Creatinine ≤ 2.0 mg/dL

- Total bilirubin normal (grade 0)

- No specific limit of total serum bilirubin for patient receiveing indinavir or
atazanavir therapy AND direct serum bilirubin ≤ 30% of total bilirubin

- AST and ALT ≤ 2.5 times upper limit of normal (grade 1)

- INR and aPTT normal

- Proteinuria < 2+

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective barrier contraception during and for up to 3
months after completion of study treatment

- Capable of complying with the study, in the opinion of the investigator

- No acute, active opportunistic infection (other than oral thrush or genital herpes)
within the past 14 days

- No other concurrent neoplasia requiring cytotoxic therapy

- No history of any of the following:

- Myocardial infarction

- Severe/unstable angina

- Coronary/peripheral artery bypass graft

- Symptomatic congestive heart failure

- Cerebrovascular accident

- Transient ischemic attack

- Pulmonary embolism

- Deep vein thrombosis

- Other significant thromboembolic event

- No known coagulopathy or bleeding diathesis

- No history of CNS, pulmonary, GI, or urinary bleeding

- No known history of drug-induced liver injury

- Resting systolic blood pressure ≤ 160 mm Hg or diastolic blood pressure ≤ 100 mm Hg

- No history of or ongoing clinically significant illness, medical condition, surgical
history, physical finding, ECG finding, or laboratory abnormality that, in the
opinion of the investigator, could affect the safety of the patient, alter the
absorption of the study drug, or impair the assessment of study results


- More than 4 weeks since prior and no other concurrent anti-neoplastic therapy for KS,
including chemotherapy, radiotherapy, local therapy, or biological therapy

- More than 60 days since prior local therapy for any KS-indicator lesion unless the
lesion has clearly progressed since treatment

- Any prior local therapy for indicator lesions (regardless of the elapsed time)
should not be allowed unless there is evidence of clear-cut progression of that

- More than 28 days since prior and no other concurrent investigational drugs or
therapy (other than antiretroviral therapy or agents available on a treatment IND)

- More than 30 days since prior major surgery and recovered

- More than 14 days since prior treatment for an acute infection (other than oral
thrush or genital herpes) or other serious medical illness

- No concurrent surgical procedures

- No concurrent systemic corticosteroid therapy, other than replacement doses

- No concurrent anticoagulant therapy, including warfarin, heparin (including low
molecular weight heparin), or antiplatelet drugs (e.g., clopidogrel bisulfate)

- Concurrent aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) allowed
provided the dose does not exceed the maximum recommended dose

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and Toxicity of Anti-VEGF Small Molecule PTC299

Outcome Description:

Patients who experienced an adverse event of grade 3 or greater

Outcome Time Frame:

All study visits

Safety Issue:


Principal Investigator

Susan E. Krown, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Federal Government

Study ID:




Start Date:

September 2008

Completion Date:

December 2010

Related Keywords:

  • Kaposi's Sarcoma
  • HIV infection
  • AIDS-related Kaposi sarcoma
  • recurrent Kaposi sarcoma
  • Treatment Experienced
  • Sarcoma, Kaposi
  • Sarcoma



Memorial Sloan-Kettering Cancer Center New York, New York  10021
Beth Israel Deaconess Medical Center Boston, Massachusetts  02215
Cancer Research Center of Hawaii Honolulu, Hawaii  96813
USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California  90033-0804
Rebecca and John Moores UCSD Cancer Center La Jolla, California  92093-0658
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center Columbus, Ohio  43210-1240
UCLA Clinical AIDS Research and Education (CARE) Center Los Angeles, California  90024
Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center Seattle, Washington  98111